146954-76-9

Usage

Uses

Used in Pharmaceutical Industry:
N4-Benzoyl-2'-deoxy-2'-fluorocytidine is used as a potential antiviral agent for its demonstrated activity against viruses such as HIV and hepatitis B virus. Its unique molecular structure allows it to interfere with viral replication processes, offering a new approach to treating viral infections and contributing to the development of novel antiviral drugs.
If further applications are identified in the future based on additional research or materials, they can be listed as follows:
Used in Research Applications:
N4-Benzoyl-2'-deoxy-2'-fluorocytidine serves as a valuable compound in scientific research for studying the mechanisms of viral replication and the development of antiviral resistance. It aids researchers in understanding how nucleoside analogues can be modified to create more effective antiviral therapies.
Used in Drug Development:
In the drug development sector, N4-Benzoyl-2'-deoxy-2'-fluorocytidine is utilized as a lead compound for the creation of new pharmaceuticals. Its antiviral properties are harnessed to design drugs that can combat viral diseases, potentially leading to more effective treatments with fewer side effects.

Upstream product

• 93-97-0 benzoic acid anhydride 
• 10212-20-1 2'-deoxy-2'-fluorocytidine 
• 65-46-3 CYTIDINE 
• 13089-48-0 N₄-benzoylcytidine 
• 69304-43-4 1-[3,5-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-β-D-ribofuranosyl]-N⁴-benzoylcytosine 
• 196928-90-2 Acetic acid (2R,3R,4R,5R)-2-acetoxymethyl-4-fluoro-5-[4-(3-nitro-[1,2,4]triazol-1-yl)-2-oxo-2H-pyrimidin-1-yl]-tetrahydro-furan-3-yl ester 
• 56287-17-3 2'-deoxy-2'-fluorouridine 
• 10212-13-2 3’,5’-O-acetyl-2’-deoxy-2’-fluorouridine 

Downstream Products

• 177086-37-2 C₃₀H₃₀FN₃O₆ 
• 146954-77-0 N⁴-benzoyl-5'-O-(4,4'-dimethoxytrityl)-2'-fluoro-2'-deoxycytidine 
• 161442-19-9 N⁴-benzoyl-2'-deoxy-2'-fluoro-5'-O-(4,4'-dimethoxytrityl)cytidine 3'-(β-cyanoethyl N,N-diisopropylphosphoramidite) 

Relevant academic research and scientific papers

Synthesis method for azvudine

The invention discloses a synthesis method for azvudine. The method comprises the following steps of carrying out a hydroxyl substitution reaction on a compound 4 and an iodine elementary substance toobtain a compound 5, carrying out an elimination reaction on an iodo group in the compound 5 to obtain a compound 6, reacting the compound 6 with azide under the catalysis of ICl to obtain a compound7, carrying out an iodine substitution reaction on the compound 7 and carboxylic acid to obtain a compound 8, and carrying out an amino and hydroxyl deprotection reaction on the compound 8 to obtaina compound 9, namely the alzvudine. Compared with an existing synthesis method, the synthesis method has the advantages of short synthesis route, shortened reaction time, mild reaction conditions andeasily controlled reaction process, can be used for preparing the alzvudine with the lower cost, and has a very good application prospect.

Azido nucleosides and nucleotide analogs

Disclosed herein are 4′-azido-substituted nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of 4′-azido-substituted nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a 4′-azido-substituted nucleoside, a nucleotide and/or an analog thereof. Examples of viral infections include a respiratory syncytial viral (RSV) and influenza infection.

SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF

Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a norovirus, with a nucleoside, a nucleotide and an analog thereof.

Antisense modulation of CD40 ligand expression

Antisense compounds, compositions and methods are provided for modulating the expression of CD40 ligand. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding CD40 ligand. Methods of using these compounds for modulation of CD40 ligand expression and for treatment of diseases associated with expression of CD40 ligand are provided.

Modulation of CEACAM1 expression

Compounds, compositions and methods are provided for modulating the expression of CEACAM1. The compositions comprise oligonucleotides, targeted to nucleic acid encoding CEACAM1. Methods of using these compounds for modulation of CEACAM1 expression and for diagnosis and treatment of disease associated with expression of CEACAM1 are provided.

Antisense modulation of polo-like kinase expression

Antisense compounds, compositions and methods are provided for modulating the expression of polo-like kinase. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding polo-like kinase. Methods of using these compounds for modulation of polo-like kinase expression and for treatment of diseases associated with expression of polo-like kinase are provided.

Antisense modulation of CDC14A expression

Antisense compounds, compositions and methods are provided for modulating the expression of CDC14A. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding CDC14A. Methods of using these compounds for modulation of CDC14A expression and for treatment of diseases associated with expression of CDC14A are provided.

Antisense modulation of perilipin expression

Antisense compounds, compositions and methods are provided for modulating the expression of perilipin. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding perilipin. Methods of using these compounds for modulation of perilipin expression and for treatment of diseases associated with expression of perilipin are provided.

Antisense modulation of resistin expression

Antisense compounds, compositions and methods are provided for modulating the expression of resistin. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding resistin. Methods of using these compounds for modulation of resistin expression and for treatment of diseases associated with expression of resistin are provided.

Antisense modulation of EDG5 expression

Antisense compounds, compositions and methods are provided for modulating the expression of EDG5. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding EDG5. Methods of using these compounds for modulation of EDG5 expression and for treatment of diseases associated with expression of EDG5 are provided.